Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial.
Cullen NC, Novak P, Tosun D, Kovacech B, Hanes J, Kontsekova E, Fresser M, Ropele S, Feldman HH, Schmidt R, Winblad B, Zilka N. Cullen NC, et al. EBioMedicine. 2024 Jan;99:104923. doi: 10.1016/j.ebiom.2023.104923. Epub 2023 Dec 14. EBioMedicine. 2024. PMID: 38101301 Free PMC article. Clinical Trial.
Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease.
Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, Hansson O, Parnetti L, Constantinescu R, Wildsmith K, Chen HH, Beach TG, Lashley T, Zetterberg H, Blennow K, Höglund K. Cicognola C, et al. Among authors: cullen nc. Acta Neuropathol. 2019 Feb;137(2):279-296. doi: 10.1007/s00401-018-1948-2. Epub 2018 Dec 13. Acta Neuropathol. 2019. PMID: 30547227 Free PMC article.
Comparing progression biomarkers in clinical trials of early Alzheimer's disease.
Cullen NC, Zetterberg H, Insel PS, Olsson B, Andreasson U; Alzheimer’s Disease Neuroimaging Initiative; Blennow K, Hansson O, Mattsson-Carlgren N. Cullen NC, et al. Ann Clin Transl Neurol. 2020 Sep;7(9):1661-1673. doi: 10.1002/acn3.51158. Epub 2020 Aug 11. Ann Clin Transl Neurol. 2020. PMID: 32779869 Free PMC article.
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, Borroni E, Janelidze S, Ohlsson T, Jögi J, Ossenkoppele R, Palmqvist S, Mattsson-Carlgren N, Klein G, Stomrud E, Hansson O. Leuzy A, et al. Among authors: cullen nc. JAMA Neurol. 2022 Feb 1;79(2):149-158. doi: 10.1001/jamaneurol.2021.4654. JAMA Neurol. 2022. PMID: 34928318 Free PMC article.
Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.
Cullen N, Janelidze S, Palmqvist S, Stomrud E, Mattsson-Carlgren N, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Cullen N, et al. Neurology. 2022 Mar 1;98(9):e958-e967. doi: 10.1212/WNL.0000000000013228. Epub 2021 Dec 22. Neurology. 2022. PMID: 34937781 Free PMC article.
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.
Smith R, Cullen NC, Pichet Binette A, Leuzy A, Blennow K, Zetterberg H, Klein G, Borroni E, Ossenkoppele R, Janelidze S, Palmqvist S, Mattsson-Carlgren N, Stomrud E, Hansson O; Alzheimer's Disease Neuroimaging Initiative. Smith R, et al. Among authors: cullen nc. Alzheimers Dement. 2023 Jun;19(6):2497-2507. doi: 10.1002/alz.12875. Epub 2022 Dec 14. Alzheimers Dement. 2023. PMID: 36516028
36 results